Do you want to read an article? Please log in or register.
Deep remission with vedolizumab in patients with moderately to severely active ulcerative colitis: a GEMINI 1 post hoc analysis
Inflammatory Bowel Disease
Related content
Inflammatory Bowel Disease
Fecal Calprotectin Responses Following Induction Therapy With Vedolizumab in Moderate to Severe Ulcerative Colitis: A Post Hoc Analysis of GEMINI 1
Inflamm Bowel Dis.
Reinisch W, Bressler B, Curtis R, Parikh A, Yang H, Rosario M, Røseth A, Danese S, Feagan B, Sands BE, Ginsburg P, Dassopoulos T, Lewis J, Xu J, Wyant T
doi: 10.1093/ibd/izy304.
Inflammatory Bowel Disease
Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis
Inflamm Bowel Dis.
Feagan BG, Schreiber S, Wolf DC, Axler JL, Kaviya A, James A, Curtis RI, Geransar P, Stallmach A, Ehehalt R, Bokemeyer B, Khalid JM, O'Byrne S
doi: 10.1093/ibd/izy323.
RECOMMENDED
Inflammatory Bowel Disease
First- and Second-line Pharmacotherapies for Patients with Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis
★ 2
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
Clin Gastroenterol Hepatol.
Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ
doi: 10.1016/j.cgh.2020.01.008.
Inflammatory Bowel Disease
The association between disease activity and patient-reported outcomes in patients with moderate-to-severe ulcerative colitis in the United States and Europe
BMC Gastroenterol.
Armuzzi A, Tarallo M, Lucas J, Bluff D, Hoskin B, Bargo D, Cappelleri JC, Salese L, daCosta DiBonaventura M
doi: 10.1186/s12876-020-1164-0.
Inflammatory Bowel Disease
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
N Engl J Med.
Sands BE, Peyrin-Biroulet L, Loftus EV Jr, Danese S, Colombel JF, Törüner M, Jonaitis L, Abhyankar B, Chen J, Rogers R, Lirio RA, Bornstein JD, Schreiber S, VARSITY Study Group.
doi: 10.1056/NEJMoa1905725.
Inflammatory Bowel Disease
Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors
Am J Gastroenterol.
Dulai PS, Battat R, Barsky M, Nguyen NH, Ma C, Narula N, Mosli M, Vande Casteele N, Boland BS, Prokop L, Murad MH, DʼHaens G, Feagan BG, Sandborn WJ, Jairath V, Singh S
doi: 10.14309/ajg.0000000000000596.
Inflammatory Bowel Disease
Corticosteroid-Free Remission vs Overall Remission in Clinical Trials of Moderate-Severe Ulcerative Colitis and Crohn's Disease
Inflamm Bowel Dis.
George J, Singh S, Dulai PS, Ma C, Nguyen T, Feagan BG, Sandborn WJ, Jairath V
doi: 10.1093/ibd/izz193.
Inflammatory Bowel Disease
Vedolizumab in Combination With Corticosteroids for Induction Therapy in Crohn's Disease: A Post Hoc Analysis of GEMINI 2 and 3
Inflamm Bowel Dis.
Sands BE, Van Assche G, Tudor D, Akhundova-Unadkat G, Curtis RI, Tan T
doi: 10.1093/ibd/izy384.
Inflammatory Bowel Disease
Indirect comparison of vedolizumab and adalimumab for biologic-naive patients with ulcerative colitis
Scand J Gastroenterol.
Dignass AU, Siegmund B, Goertz R, Schneidewind G, Fanter L
doi: 10.1080/00365521.